Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 May 30;14(2):138-143.
doi: 10.1159/000523756. eCollection 2022 May-Aug.

A Case of Recalcitrant Circinate Generalized (Lapière) Psoriasis Successfully Treated with Risankizumab

Angelo Ruggiero  1 , Wanda Lauro  1 , Gabriella Fabbrocini  1 , Chiara Miano  1 , Alessia Villani  1 , Claudio Marasca  1
Affiliations
Case Reports

A Case of Recalcitrant Circinate Generalized (Lapière) Psoriasis Successfully Treated with Risankizumab

Angelo Ruggiero et al. Case Rep Dermatol. .

Abstract

Circinate (Lapière) psoriasis represents a rare variety of generalized subacute pustular psoriasis clinically characterized by rapid onset of annular circinate lesions with micro-pustules at the borders without classic plaque psoriasis manifestations. Most reported cases have been described in childhood with a relative benign course, fast and long-term remission after treatment. However, the recalcitrant course may result in an important negative impact on patients' quality of life. Many systemic treatments have been reported for the management of moderate to severe forms, with variable clinical outcomes. However, data about the use of biologics in this rare psoriasis subtype are still lacking. Herein, we report the first case of circinate psoriasis unresponsive to methotrexate and almost all classes of biologics approved for psoriasis (anti-tumour necrosis factor (TNF), anti-interleukin (IL)-12/23, and anti-IL-17) which was successfully treated with risankizumab (anti-IL-23).

Keywords: Circinate psoriasis; Lapiere's psoriasis; Risankizumab.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Figures

Fig. 1
Fig. 1
Clinical manifestations of severe circinate psoriasis at baseline (a–c) and after 12 weeks of treatment with risankizumab (d–f).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Liao PB, Rubinson R, Howard R, Sanchez G, Frieden IJ. Annular pustular psoriasis: most common form of pustular psoriasis in children: report of three cases and review of the literature. Pediatr Dermatol. 2002 Jan–Feb;19((1)):19–25. - PubMed
    1. Resneck JS, Cram DL. Erythema annulare-like pustular psoriasis. Arch Dermatol. 1973;108((5)):687–8. - PubMed
    1. Navarini AA, Burden AD, Capon F, Mrowietz U, Puig L, Köks S, et al. European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol. 2017 Nov;31((11)):1792–9. - PubMed
    1. Von Zumbusch L. Psoriasis und pustuloses Exanthem. Arch Dermatol Syphilol. 1910;99:335–46.
    1. Filippeschi C, Battini ML, Tiradritti L, Mastrolorenzo A, Staderini C, Rapaccini AL, et al. A case of recurrent circinate erythematous psoriasis (Lapière) G Ital Dermatol Venereol. 1990 Aug;125((7–8)):341–3. (Italian) - PubMed

Publication types